Such a hypothesis is indeed supported by evidence that residual cells in tumors that do not achieve pCR displayed a lower HSP90 immunostaining, thereby mirroring the lack of treatment efficacy on residual tumor cell clones, similar to what is observed for Ki67 [34,35,36]. The gene discussed is HSP90AA1; the disease is neoplasm.